Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-014091
Filing Date
2025-02-14
Accepted
2025-02-14 16:14:18
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12887
2 EXHIBIT 99.1 tm254155d2_ex99-1.htm EX-99.1 5746
  Complete submission text file 0001104659-25-014091.txt   20577
Mailing Address 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014
Business Address 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014 2123395600
BAKER BROS. ADVISORS LP (Filed by) CIK: 0001263508 (see all company filings)

EIN.: 134093645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Subject) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93359 | Film No.: 25628866
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)